Second positive phase 3 dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis

Second positive phase 3 dupixent ® (dupilumab) trial confirms significant improvement s for patients with prurigo nodularis
REGN Ratings Summary
REGN Quant Ranking